TP53 and prostate cancer: The activation of K-ras and the loss of Tp53 in pancreatic tumors promote the release of CXCR2 ligands (129), while PTEN and TP53 deficiency in prostate cancer lead to the release of CXCL17, both of them enhance neutrophil recruitment and contribute to TME immune suppression (130).